Welcome to the e-CCO Library!

P660: Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Flanagan*1, P. R. Gibson2, A. Ross1, O. Rosella3, S. J. Bell1

Created: Friday, 22 February 2019, 9:41 AM
P660: The impact of COVID-19 on the provision of care for patients with Inflammatory Bowel Disease: A cross sectional survey
Year: 2021
Source: ECCO'21 Virtual
Authors: Malhi, G.(1);Mikail, M.(1);Chambers, J.(1);Khanna, R.(2);Wilson, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P661 Post-operative prophylaxis with anti-TNF in patients with Crohn’s disease who are anti-TNF experienced is associated with higher rates of prophylaxis failure
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Aharoni Golan1,2, J. Ollech1,2, I. Avni Biron1,2, Y. Broitman1,2, Y. Snir1,2, H. Banai Eran1,2, H. Leibovitzh1,2, I. Goren1,2, N. Wasserberg2,3, I. Dotan1,2, H. Yanai1,2

Created: Thursday, 30 January 2020, 10:12 AM
P661: Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn's disease: data from the ADVANCE and MOTIVATE studies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panaccione, R.(1)*;Dotan, I.(2,3);Ferrante, M.(4);Danese, S.(5,6);Bossuyt, P.(7);Kligys, K.(8);Neimark, E.(8);Zambrano, J.(8);Liao, X.(8);D'Haens, G.(9);
Created: Friday, 14 July 2023, 11:12 AM
P661: Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade®) in children with established inflammatory bowel disease: a multi-centre prospective observational study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sladek M.*1, Vultaggio A.2, Ghione S.3, Nencini F.2, Matucci A.2, Pratesi S.2, Zanieri F.4, Maggi P.M.2, Paci M.5, Ponanta-Gawron K.1, Kulig K.6, Wasilewska A.1, Lionetti P.7

Created: Wednesday, 20 February 2019, 10:36 AM
P661: Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn’s disease in the STEPSTONE trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. G. Feagan*1, G. D'Haens2, K. Usiskin3, J. Liu3, D. Paul3, R. K. Pai4

Created: Friday, 22 February 2019, 9:41 AM
P661: Pre-diagnostic vitamin D levels in Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Widbom, L.(1);Fahlander, S.(1);Stefansson, K.(1);Karling, P.(2);Hultdin, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P661: Radon exposure and inflammatory bowel disease in a radon prone area
Year: 2021
Source: ECCO'21 Virtual
Authors: Mauriz Barreiro, M.V.(1);Ruano-Raviña, A.(2);Baston-Rey, I.(1);Ferreiro-Iglesias, R.(1);Calviño-Suarez, C.(1);Barros-Dios, J.M.(2);Dominguez-Muñoz, J.E.(1);Barreiro-de Acosta, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P662 Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: A real-world retrospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Yoshimura, Soh. Okano, Minako. Sako, Masakazu. Takazoe

Created: Thursday, 30 January 2020, 10:12 AM
P662: A retrospective claims analysis on the prevalence and incidence of ulcerative colitis in Germany and the frequency of advanced therapy use
Year: 2021
Source: ECCO'21 Virtual
Authors: Mueller, S.(1);Khalid, M.(2);Patel, H.(2);Wilke, T.(3);Dittmar, A.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P662: Colorectal Cancer in Patients with Ulcerative Colitis: A National Cohort Study between 1991-2020
Year: 2022
Source: ECCO'22
Authors: Heuthorst, L.(1);Harbech , H.(1);Snijder, A.(1);Mookhoek, A.(2);D'Haens, G.(3);Vermeire, S.(4);D'Hoore, A.(5);Bemelman, W.(1);Buskens, C.(1);
Created: Friday, 11 February 2022, 3:56 PM
P662: Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lin, S.(1,2)*;Chanchlani, N.(1,2);Smith, R.(1,2);Roberts, C.(1,2);Nice, R.(3);McDonald, T.J.(3);Hamilton, B.(2);Bewshea, C.(2);Kennedy, N.A.(1,2);Goodhand, J.R.(1,2);Ahmad, T.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P662: Remission to vedolizumab is not higher in TNF-naïve compared with TNF-pre-treated patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Biedermann1, O. Mader2, P. Hruz3, P. Juillerat4, P. Michetti5, V. Pittet5, G. Rogler1, F. Seibold*2

Created: Friday, 22 February 2019, 9:41 AM
P662: Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Paschos P.1,2, Katsoula A.2, Giouleme O.*2, Tsapas A.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P662: Transmural healing evaluated by magnetic resonance enterography in paediatric Crohn’s disease patients under maintenance treatment with biologics
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Kang1, S. Oh2, T.Y. Jeon2, Y.H. Choe2*

Created: Thursday, 21 February 2019, 9:14 AM
P663 Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Rutka, K. Farkas, D. Pigniczki, K. Szántó, B. Anita, R. Bor, A. Fábián, Z. Szepes, F. Nagy, T. Molnár

Created: Thursday, 30 January 2020, 10:12 AM
P663: Long-term follow up in IBD: 10-year observational study of a UK IBD cohort.
Year: 2021
Source: ECCO'21 Virtual
Authors: Radhakrishnan, S.T.(1,2);Vasireddy, A.(3);Gallagher, K.I.(1);Hicks, L.C.(1,2); Powles, S.T.(1,4);Chong, L.(1,5);Peake, S.T.(2);Orchard, T.R.(2);Williams, H.R.T.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P663: Mild COVID-19 disease and breakthrough cases among children with inflammatory bowel disease: An update from an international registry
Year: 2022
Source: ECCO'22
Authors: Brenner, E.(1);Zhang, X.(2);Agrawal, M.(3);Ungaro, R.(3);Colombel, J.F.(3);Kappelman, M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P663: Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: An, Y.K.(1)*;Lindsay, N.(2);Allan, N.(2);Khoo, E.(1);Fernandes, R.(1);Amiss, A.(2);Pham, H.(2);Wong, K.F.(2);Ooi, S.Y.(3);Thin, L.(4);Lightowler, D.(4);Connor, S.J.(5);Williams, A.J.(5);De Cruz, P.(6);Li Wai Suen, C.(6);Kariyawasam, V.(7);Mitrev, N.(7);Ghaly, S.(8);Andrews, J.M.(9);Christensen, B.(10);Sparrow, M.P.(11);White, L.S.(12);Bryant, R.V.(13);Ding, N.(14);Leong, R.(15);Van Langenberg, D.(16);Seltenreich, H.(17);Subramaniam, K.(18);Radford-Smith, G.(3);Begun, J.(19);
Created: Friday, 14 July 2023, 11:12 AM
P663: Primary prevention of post-operative recurrence of Crohn’s disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Cañete1,2*, M. Mañosa2,3, M.J. Casanova3,4, R.C. González-Sueyro5, J. Barrio6, F. Bermejo7, P. Nos8, E. Iglesias9, E. Garcia-Planella10, J.L. Perez-Calle11, L. Ramos12, R. De Francisco13, M. Rivero14, A. Montserrat3,15, P. Navarro16, C. Taxonera17, J. Hinojosa18, A. Núñez19, M. Navarro-Llavat20, P. Ramírez-de la Piscina21, L. Fernández22, P. Almela23, R. Ríos24, A. Clos2, E. Cabré2,3, E. Domènech2,3

Created: Thursday, 21 February 2019, 9:14 AM